BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 34208794)

  • 1. Androgen Receptor Signaling in Prostate Cancer Genomic Subtypes.
    Jillson LK; Yette GA; Laajala TD; Tilley WD; Costello JC; Cramer SD
    Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34208794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistance.
    Jamroze A; Chatta G; Tang DG
    Cancer Lett; 2021 Oct; 518():1-9. PubMed ID: 34118355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptor (AR) cistrome in prostate differentiation and cancer progression.
    Wang F; Koul HK
    Am J Clin Exp Urol; 2017; 5(3):18-24. PubMed ID: 29181434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interplay between genomic alterations and androgen receptor signaling during prostate cancer development and progression.
    Nyquist MD; Dehm SM
    Horm Cancer; 2013 Apr; 4(2):61-9. PubMed ID: 23307762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
    Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
    Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting androgen receptor-independent pathways in therapy-resistant prostate cancer.
    Xu L; Chen J; Liu W; Liang C; Hu H; Huang J
    Asian J Urol; 2019 Jan; 6(1):91-98. PubMed ID: 30775252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen Receptor-Dependent Mechanisms Mediating Drug Resistance in Prostate Cancer.
    Ehsani M; David FO; Baniahmad A
    Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33810413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bipolar Androgen Therapy Followed by Androgen Receptor Inhibition as Sequential Therapy for Prostate Cancer.
    Denmeade SR; Sena LA; Wang H; Antonarakis ES; Markowski MC
    Oncologist; 2023 Jun; 28(6):465-473. PubMed ID: 37027449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
    Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB
    Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Overview of Next-Generation Androgen Receptor-Targeted Therapeutics in Development for the Treatment of Prostate Cancer.
    Mohler ML; Sikdar A; Ponnusamy S; Hwang DJ; He Y; Miller DD; Narayanan R
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Origin, Expression Regulation, and Biological Function of Androgen Receptor Splicing Variant 7 in Prostate Cancer.
    Chen Y; Lan T
    Urol Int; 2021; 105(5-6):337-353. PubMed ID: 32957106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combinatorial androgen receptor targeted therapy for prostate cancer.
    Singh P; Uzgare A; Litvinov I; Denmeade SR; Isaacs JT
    Endocr Relat Cancer; 2006 Sep; 13(3):653-66. PubMed ID: 16954423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crosstalk Between AR and Wnt Signaling Promotes Castration-Resistant Prostate Cancer Growth.
    Luo J; Wang D; Wan X; Xu Y; Lu Y; Kong Z; Li D; Gu W; Wang C; Li Y; Ji C; Gu S; Xu Y
    Onco Targets Ther; 2020; 13():9257-9267. PubMed ID: 32982312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular model for neuroendocrine prostate cancer progression.
    Chen R; Dong X; Gleave M
    BJU Int; 2018 Oct; 122(4):560-570. PubMed ID: 29569310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Strategy of Proxalutamide for the Treatment of Prostate Cancer through Coordinated Blockade of Lipogenesis and Androgen Receptor Axis.
    Gu Y; Xue M; Wang Q; Hong X; Wang X; Zhou F; Sun J; Wang G; Peng Y
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948018
    [No Abstract]   [Full Text] [Related]  

  • 17. RELA is sufficient to mediate interleukin-1 repression of androgen receptor expression and activity in an LNCaP disease progression model.
    Thomas-Jardin SE; Dahl H; Kanchwala MS; Ha F; Jacob J; Soundharrajan R; Bautista M; Nawas AF; Robichaux D; Mistry R; Anunobi V; Xing C; Delk NA
    Prostate; 2020 Feb; 80(2):133-145. PubMed ID: 31730277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen receptor and prostate cancer stem cells: biological mechanisms and clinical implications.
    Deng Q; Tang DG
    Endocr Relat Cancer; 2015 Dec; 22(6):T209-20. PubMed ID: 26285606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen Receptor Signaling in Castration-Resistant Prostate Cancer Alters Hyperpolarized Pyruvate to Lactate Conversion and Lactate Levels In Vivo.
    Zacharias N; Lee J; Ramachandran S; Shanmugavelandy S; McHenry J; Dutta P; Millward S; Gammon S; Efstathiou E; Troncoso P; Frigo DE; Piwnica-Worms D; Logothetis CJ; Maity SN; Titus MA; Bhattacharya P
    Mol Imaging Biol; 2019 Feb; 21(1):86-94. PubMed ID: 29748904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen Receptor Signaling and Metabolic and Cellular Plasticity During Progression to Castration Resistant Prostate Cancer.
    Uo T; Sprenger CC; Plymate SR
    Front Oncol; 2020; 10():580617. PubMed ID: 33163409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.